Pharmaceuticals, Biotechnology and Life Sciences
Novartis has announced results of a Phase III pivotal study showing Afinitor (everolimus) tablets reduced the risk of progression by 52% vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.
Allergan plc announced on Friday that it has launched a generic version of Janssen’s Invega (paliperidone extended-release tablets) in the…
Janssen-Cilag International NV has announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Murphy Farm Hay and Feed Company of Louisburg North Carolina have initiated a voluntary limited recall of alfalfa hay due to…
The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to…
Johnson & Johnson Consumer Inc. has completed the divestiture of Splenda Brand to Heartland Food Products Group. Johnson & Johnson announced…
The European Committee for Medicinal Products for Human Use (CHMP) has recommended Bayer’s aflibercept solution for injection into the eye…
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved in Japan Bayer’s oral Factor Xa inhibitor Xarelto (rivaroxaban) for the treatment…
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
Novartis has announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and…